Precision radiation plus immunotherapy shows promise for tough lung cancers
NCT ID NCT03916419
First seen Nov 12, 2025 · Last updated May 17, 2026 · Updated 19 times
Summary
This study tested a new way to treat advanced lung cancer (stages IIB to IIIC) that cannot be removed with surgery. It combined MRI-guided, high-dose radiation with standard chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this approach is safe and helps control the cancer. The study included 26 people and focused on tracking side effects and how well the cancer responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.